The treatment reduced the levels of diverse tumorigenic proteins participating in myeloma progression. Remarkably, it was noted that formononetin blocked persistent PI3K/AKT, NF-κB, and AP-1 activations. Here, NFKB1 is linked to plasma cell myeloma.